Biological studies of samarium-153 bleomycin complex in human breast cancer murine xenografts for therapeutic applications

Radiochimica Acta

Volumn 98, Issue 4, 2010, Pages 237-242

  Bahrami Samani, A ^a   Ghannadi Maragheh, M ^a,b   Jalilian, A R ^b   Mazidi, M ^b  

^a AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

^b NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956128870     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2010.1713     Document Type: Article

References (27)

1. Korppi-Tommola, T., Huhmar, H., Aronen, H. J.: 111In-Labelled bleomycin complex for the differentiation of high- and low-grade gliomas. Nucl. Med. Commun. 20. 145-152 (1999).
2. Heffeter, P., Jakupec, M. A., Korner, W., Wild, S., von Keyserlingk, N. G., Elbling, L., Zorbas, H., Korynevska, A., Knasmuller, S., Sutterlulya, H., Micksche, M., Keppler, B. K., Berger, W.: Anticancer activity of the lanthanum compound [tris(1,10-phenanthrolinc)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem. Pharmacol. 71, 426-440 (2006).
3. Zhao, O., Li, F., Lin, H. Lin, H.: Synthesis, characterization and biological activity of complexes of lanthanum(III) with 2-(1′-pheny1- 2′-carboxy1-3′-aza-n-buty1)-1,10-phenanthroline and 2-(1′-p-phenol-2′-carboxy1-3′-aza-n-buty1)-1, 10-phenanthroline. Bioorg. Med. Chem. IS, 533-540 (2007).
4. Eary, J. E, Collins, C, Stabin, M.. Vernon, C, Petersdorf, S., Baker. M., Hartnett, S.. Ferency, S.. Addison, S. J..Appelbaum, F. et ah: Samarium-153-EDTMP biodistribution and dosimetry estimation. J. Nucl. Med. 34, 1031-1036 (1993).
5. Anderson, P., Nunez, R.: Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev. Anticancer Ther. 7, 1517-1527 review (2007).
6. Majali, M. A., Mathakar, A. R,, Shimpi, II. II.. Banerjee, S., Samuel, G.: Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker. Appl. Radiat. Isot. 53, 987-991 (2000).
7. Kraeber-Bodéré F., Mishra, A., Thédrez, P., Faivre-Chauvet, A., Bardies, M., Imai, S., Le Boterff, J., Chatal, J. E: Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur. J. Nucl. Med. 23, 560-567 (1996).
8. Prat a, M. I., Santos, A. C, Neves, M., Geraldes, C. F., de Lima, J. J.: 153Sm- and 111In-DTPA derivatives with high hepatic specificity: in vivo and in vitro studies. J. Inorg. Biochem. 91, 312-319 (2002).
9. Firestone, R. B., Shirley, V. S., Baglin, C. M Zipkin, J.: Table of Isotopes. 8th Edn. (CDROM), Version 1.0, Wiley-Intcrscience, New York (1996).
10. Misra, S. N., Gagnani, M. A., Shukla, R. S.: Biological and clinical aspects of lanthanide coordination compounds. Bioinorg. Chem. Appl. 2, 155-192 (2004).
11. Kostova, I.: Lanthanides as anticancer agents, Curr. Med. Chem. Anticancer Agents 5, 591-602 Review (2005).
12. Jaaskela-Saari,H. A., Kairemo, K. J., Ramsay, H. A., Grenman, R.: Labelling of bleomycin with auger-emitter increases cytotoxicity in squamous-cell cancer cell lines. Intl. J. Radiat. Biol. 73, 565-570(1998).
13. Stern, P. II., Halpern, S. E., TIagan,P.L., Howell, S. B., Dabbs, J. E., Gordon, R. M.: Cytotoxic activity, tumor accumulation and tissue distribution of ruthenium-103-labeled-bleomycin. J. Nat. Cancer Inst. 807-811 (1981).
14. Brooks, R. C, Carnochan, P., Vollano, J. F., Powell, Z., Sasabows-ki, J. K., Martellucci, S., Darkes, M. C, Fricker,S. P., Murrer, B. A.: Metal complexes of bleomycin: evaluation [Rh-105]-bleomycin for use in targeted radiotherapy. Nucl. Med. Biol. 26, 421-430(1999).
15. Jalilian, A. R., Shirazi, B., Aboudzadeh, R. et al.: [T1-201](III)- bleomycin for tumor imaging. Radiochim. Acta 94, 453-459 (2006).
16. Jalilian, A. R., Rowshanfarzad, P., Sabet, M., Novinrooz, A., Raisali, G.: Preparation of [Ga-66]bleomycin complex as a possible PET radiopharmaceutical. J. Radioanal. Nucl. Chem. 264, 617-621 (2005).
17. Ferro-Flores, G., De Mara Ramrez, F., Tendilla, J. I., Pimentel-Gonzlez, G., Murphy, C. A., Melndcz-Alafort, L., Ascencio, J. A.. Croft, B. Y.: Preparation and pharmacokinetics of samarium(III)-153-labeled DTPA-bis-biotin. Characterization and theoretical studies of the samarium(IIT)-152, conjugate. Bioconjug. Chem. 10, 726(1999).
18. Jalilian, A. R., Fateh, B., Ghergherehchi.M., Karimian, A.: Development of [Zn-62]bleomycin as a possible PET tracer. Nuk-leonika 50, 143-148 (2005).
19. Jalilian, A. R., Zandi. H., Sardari D., Akhlaghi M., Rowshanfarzad, P., Saddadi, F, Majdabadi. A., Preparation and biological evaluation of [Cu-61]bleomycin complex as a possible PET radiopharmaceutical, Nukleonika 54, 135-141 (2009).
20. http://mousecanceiinodel.com/breast.aspx.
21. Bahrami-Samani, A., Jalilian, A. R., Yousefnia, II., Garousi,J., Moradkhani. S., Preparation of 153Sm-bleomycin for targetted therapy. J. Nucl. Sci. Technique (2009), in press.
22. Reynolds, J. E.: Martinadale, the Extra Pharmacopoeia. 31st Edn., Royal Pharmaceutical Society, London (1996), pp. 546-547.
23. Melnyk, D. L., Horwitz, S. B., Peisach, J.: The oxidation-reduction potential of copper-bleomvcin. Inorgan. Chim. Acta 138, 75-78 (1987).
24. Anthoiine, W. E., Soiaiman, D., Saryan, L. A., Petering, D. H.: Studies on the chemical reactivity of copper bleomycin. J. Inorg. Biochem. 11, 7544 (1982).
25. Takita, T., Umezawa, Y., Saito, S. I. et al.: Retro-synthetic manipulation of bleomycins, Tet. Lett. 123, 521-524 (1982).
26. Welwyn, H.: Proceedings of First International Symposium on Bleomycin, London, Lundbeck Ltd.. 1972-1974 (1973).
27. Jalilian, A. R., Mirzaii, M., Karimian, A., Moafian, J., Aslani, G., Moradkhani, S.: Preparation of [In-111]bleomycin. Iran J. Nucl. Med. 23, 19-26 (2005).